Literature DB >> 8694708

Identification of glycosaminoglycans in age-related macular deposits.

M Kliffen1, C M Mooy, T M Luider, J G Huijmans, S Kerkvliet, P T de Jong.   

Abstract

We investigated the presence and localization of glycosaminoglycans in basal laminar deposit and drusen in age-related maculopathy. Conventional histological staining techniques and monoclonal antibodies specific for several glycosaminoglycans were used on paraffin-embedded human maculae. Furthermore, macular homogenates were analyzed with two-dimensional electrophoresis. Quantitative analysis of glycosaminoglycans was done spectrophotometrically using dimethylmethylene blue. Immunohistochemically, all basal laminar deposit stained positive for chondroitin 4-sulfate and focally positive for heparan sulfate proteoglycan. Drusen were not stained with any of the monoclonal antibodies. With two-dimensional electrophoresis, it was demonstrated that macular extracts with and without age-related maculopathy contained chondroitin sulfate. Heparan sulfate was only expressed in maculae with age-related maculopathy. The total amount of glycosaminoglycans was significantly higher in maculae with basal laminar deposit than in maculae without basal laminar deposit (P = .001). There were significant differences in the amount and composition of glycosaminoglycans between maculae with and without age-related maculopathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694708     DOI: 10.1001/archopht.1996.01100140217021

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  13 in total

1.  The APO(*)E3-Leiden mouse as an animal model for basal laminar deposit.

Authors:  M Kliffen; E Lutgens; M J Daemen; E D de Muinck; C M Mooy; P T de Jong
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

2.  Increased expression of angiogenic growth factors in age-related maculopathy.

Authors:  M Kliffen; H S Sharma; C M Mooy; S Kerkvliet; P T de Jong
Journal:  Br J Ophthalmol       Date:  1997-02       Impact factor: 4.638

3.  Advanced glycation endproduct changes to Bruch's membrane promotes lipoprotein retention by lipoprotein lipase.

Authors:  Marisol Cano; Natalia Fijalkowski; Naoshi Kondo; Sonny Dike; James Handa
Journal:  Am J Pathol       Date:  2011-06-12       Impact factor: 4.307

Review 4.  Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.

Authors:  Karen M Gehrs; Don H Anderson; Lincoln V Johnson; Gregory S Hageman
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

5.  Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye.

Authors:  R N Fariss; S S Apte; B R Olsen; K Iwata; A H Milam
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

6.  The Evolution of the Plateau, an Optical Coherence Tomography Signature Seen in Geographic Atrophy.

Authors:  Anna C S Tan; Polina Astroz; Kunal K Dansingani; Jason S Slakter; Lawrence A Yannuzzi; Christine A Curcio; K Bailey Freund
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-04-01       Impact factor: 4.799

Review 7.  Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins.

Authors:  Christine A Curcio; Mark Johnson; Jiahn-Dar Huang; Martin Rudolf
Journal:  Prog Retin Eye Res       Date:  2009-08-19       Impact factor: 21.198

8.  Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy.

Authors:  Goldis Malek; Chuan-Ming Li; Clyde Guidry; Nancy E Medeiros; Christine A Curcio
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 9.  Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration.

Authors:  Christine A Curcio; Mark Johnson; Jiahn-Dar Huang; Martin Rudolf
Journal:  J Lipid Res       Date:  2009-09-29       Impact factor: 5.922

10.  Effect of TNF-alpha on human ARPE-19-secreted proteins.

Authors:  Eunkyung An; Heather Gordish-Dressman; Yetrib Hathout
Journal:  Mol Vis       Date:  2008-12-11       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.